Although breathing is an involuntary, automatic process, for many people it can be difficult. Chronic obstructive pulmonary disease (COPD) is a serious illness that prevents normal lung function, and its early onset in adults can be caused by deficiency of alpha1antitrypsin (AATD), a genetic disorder.1 More than 185,000 people are living with severe AATD worldwide.2 As a pioneer and leader in alpha1-antitrypsin treatment (AAT), we are looking to expand our reach and administration options for patients with this condition to help reduce the rate of COPD mortality.

  • Alternative delivery options for AAT
    Continuing our commitment to patients with AATD, we are researching more convenient routes of administration, such as subcutaneous and inhaled delivery alternatives. 
  • Expanding AAT into new indications
    We have a dedicated focus on expanding AAT treatment to additional pulmonology indications beyond emphysema, such as non–cystic fibrosis bronchiectasis.

1 de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 2014;276(4):311-35. doi: 10.1111/joim.12239

2 Grifols Investor Relations, 2021 Investor and Analyst Day


Developing Treatments

Patients are at the center of our far-ranging scientific research to develop therapeutic solutions to some of the world’s most pressing healthcare challenges.

Learn more